Interview With Douglas K. Gordon

Today we’ll discuss More MindMed Catalysts: MMED MMEDF Stock Opportunity (Plus Jr & Kevin O’Leary comments)

Today’s episode is a short follow up video to our last episode, where we looked at the catalysts for MindMed and MindMed stock in 2021.

We have already covered the NASDAQ uplisting, Clinical trial updates that MindMed will give this year and Conference calls and possible financing deals. But of course, we missed a few of important possible catalysts, as you guys so rightly pointed out.
So in this episode we are briefly going to run through them.

So what else can MindMed and MMED/MMEDF investors expect this year?

1. The imminent launch of the first Psychedelic Medicines ETF, The North American Psychedelics Index (PSYK)
-When will it launch?
-In what manner will it affect MindMed
-And how much it will influence MindMed’s stock price

2. Atai Life Sciences expected IPO how that’ll affect MindMed
– How will the IPO of another big rival will affect MMED/MMEDF?

3. Potential catalyst of Partnerships, Mergers and Acquisitions
-Coming directly from an Interview with JR Rahn and Kevin O’Leary

Unlike the 1st two catalysts we discuss here, as well as a potential Nasdaq uplisting, future partnerships mergers and acquisitions would affect MindMed’s long term value, and their ability to develop, produce and distribute game changing medicines.

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com

https://mindmed.co/news/press-release/mindmed-expands-psychedelic-microdosing-division-adds-groundbreaking-study-evaluating-lsd-microdosing-through-next-gen-digital-clinical-markers/

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMed #MMED #MMEDF

Donate to MAPS: https://maps.org/about-maps/our-team/

Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight

Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight

To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/

In today’s episode of Psychedelic Spotlight Podcast, James Hallifax from The Psychedelic Investor, had the pleasure of interviewing Rick Doblin, founder of MAPS. When it comes to psychedelic research, the questions of whether psychedelics can help with mental health, and the de-stigmatization of psychedelics, Rick Doblin is the certified G.O.A.T.

Can MDMA treat PTSD? Rick Doblin (and the science) says YES!

Should psychedelics be legalized? Rick Doblin (and facts and logic) say YES!

Did MDMA save the world from World War III? Rick Doblin says… okay well probably not. But it may have played a role!

To learn more about MAPS and their clinical trial, visit maps.org
While you are there, if you are feeling generous and want to donate to a good cause, MAPS is a charity.

Links:
MDMA and the Soviets
https://thebulletin.org/2021/12/psychedelics-the-newest-tool-in-nuclear-negotiations/

CBS MDMA for Veterans Interview
https://www.cbsnews.com/news/mdma-ecstasy-psychedelics-treating-veterans-ptsd/

Today Show MDMA for Veterans Interview
https://www.today.com/health/mdma-ptsd-study-veteran-shares-experience-rcna4495

#RickDoblin #MDMA #PSYCHEDELICS

NEW BUY RATINGS, More Partnerships and Government Awards for psychedelic inspired companies! In this episode, we’ll take a look at the smaller psychedelic medicine companies such as Mydecine, Entheon Biomedical, Braxia, Small Pharma, Silo Therapeutics and Bright Minds Sciences.

Enjoy the episode!

Timestamps:

0:00 – Intro
0:44 – Mydecine (MYCO/ MYCOF) Unveils Artificial Intelligence Drug Discovery Program
2:21 – Braxia Scientific (OTC:BRAXF, CSE: BRAX) Awarded Government of Canada Funding To Complete The First Ever Ketamine Clinical Trial Testing For Bipolar Depression
3:51 – Partnership Between Entheon / SILO Pharma (OTC:ENTBF, CSE:ENBI) (OTC: SILO)
6:59 – Bright Minds (OTC: BMBIF, CSE: DRUG) Announces Application to List on Nasdaq
8:43 – Small Pharma (TSXV: DMT) – Price Target of C$5

Links:

Mydecine (OTC: MYCOF, NEO: MYCO) Unveils Artificial Intelligence Drug Discovery Program, in conjunction with the University of Alberta:
https://www.psychedelicfinance.com/articles/mydecine-unveils-artificial-intelligence-drug-discovery-program

Braxia Scientific (OTC:BRAXF, CSE: BRAX) Awarded Government of Canada Funding To Complete The First Ever Ketamine Clinical Trial Testing For Bipolar Depression:
https://braxiascientific.com/news/braxia-scientific-awarded-government-of-canada-funding-to-complete-first-of-its-kind-ketamine-clinical-trial-for-bipolar-depression/

Partnership Between Entheon / SILO Pharma (OTC:ENTBF, CSE:ENBI) (OTC: SILO):
https://thecannabisstock.com/2021/06/17/entheon-biomedicals-wholly-owned-subsidiary-halugen-life-sciences-and-silo-wellness-announces-psychedelics-genetic-test-kit-partnership/

Bright Minds (OTC: BMBIF, CSE: DRUG) Announces Application to List on Nasdaq:
https://psilocybinalpha.com/news/bright-minds-biosciences-announces-application-to-list-on-nasdaq

Small Pharma (TSXV: DMT) – Roth Capital Initiates Coverage On Small Pharma with Buy Rating, Announces Price Target of C$5:
https://www.benzinga.com/news/21/06/21452074/roth-capital-initiates-coverage-on-small-pharma-with-buy-rating-announces-price-target-of-c-5

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Website: https://thepsychedelicinvestor.com/
Music: www.bensound.com
editing:@themyaholy
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#Mydecine #Entheon #MYCO

Here are our Top 5 Best Psychedelic Stock Picks for 2021. For those who have watched our top 5 shroom stocks for 2020, you might notice that some stocks have stayed and others have been replaced because they have proven to be worthy of The Psychedelic Investor’s list by filling in the top 3 factors that we look at before investing in the psychedelic medicines industry, such as:
Clinical Trial Progress
Molecules & Compounds Pipeline
The Company’s war chest to sustain growth as a biotech company in a new industry

But why invest in psychedelic stocks?
Ever since last year, celebrity investors such as Kevin O’Leary and Peter Thiel decided to invest in the psychedelic/ shroom stocks industry, the industry grew from 2 or 3 companies to approximately 30 in 2021. This is probably one of the main reasons why we call this phenomenon the SHROOM BOOM!
But why do such investors seem to believe so much in the potential explosive growth of psychedelic stocks?
1. Psychedelics have been shown in many recent clinical trials to help a variety of mental health issues, from addiction, to depression to PTSD and more.
2.These psychedelic companies are attempting to disrupt the 100 billion annual industry for mental health pharmaceuticals.
3.These psychedelic compounds have the potential to help millions world wide, this also presents an amazing opportunity for early investors.
4.Smart investors might realize that rather than going all in on one company in the field, it is probably best to diversify your risk and create a Psychedelic Medicines portfolio.

So our top 5 Shroom Stock Pics for 2021 are:
5. Cybin ( CYBN on NEO & CLXPF on the OTC)
4. Numinus Wellness (LKYSF on the OTC & NUMI on the TSX)
3. Compass Pathways (CMPS on Nasdaq)
2. Atai Life Sciences – Soon to IPO on the Nasdaq
1 Mind Medicine or MindMed (MMED on NEO MNMD on Nasdaq & MMQ on FRA)
Link to Cybin (CYBN) : https://www.cybin.com/
Link to Numinus (NUMI) : https://numinus.ca/
Link to Compass Pathways (CMPS) : https://ir.compasspathways.com/static-files/fe6cc477-a2ee-4b4a-bd46-8f8df0b62f30
Link To Atai life Sciences: https://www.atai.life/
Linke To MindMed (MMED / MNMD / MMQ) https://mindmed.co/

Timestamps:
0:00 – Intro
1:58 – Ranking criteria
3:42 – Cybin (CYBN) ( CLXPF)
6:24 – Numinus Wellness ( NUMI)
10:04 – Compass Pathways (CMPS)
13:52 – Atai Life Sciences
18:50 – MindMed ( MMED / MNMD/ MMQ )

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

Clinical trials :

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #PsychedelicStocks #CMPSStock